Tag: OpRegen

October 20, 2016

BioTime to Present OpRegen® Clinical Trial Data at ISOPT Clinical Symposium

BioTime, a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the...
June 10, 2016

BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program

ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on...